Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3–5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capaci...

Full description

Bibliographic Details
Main Authors: Flore Gouel, Anne-Sophie Rolland, Jean-Christophe Devedjian, Thierry Burnouf, David Devos
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2019.00835/full
_version_ 1819263605470658560
author Flore Gouel
Anne-Sophie Rolland
Jean-Christophe Devedjian
Thierry Burnouf
Thierry Burnouf
Thierry Burnouf
David Devos
David Devos
author_facet Flore Gouel
Anne-Sophie Rolland
Jean-Christophe Devedjian
Thierry Burnouf
Thierry Burnouf
Thierry Burnouf
David Devos
David Devos
author_sort Flore Gouel
collection DOAJ
description Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3–5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capacities in the central nervous system—e.g., development, plasticity, maintenance, neurogenesis—neurotrophic growth factors (NTF) have been exploited for therapeutic strategies in ALS for decades. In this review we present the initial strategy of using single NTF by different routes of administration to the use of stem cells transplantation to express a multiple NTFs-rich secretome to finally focus on a new biotherapy based on the human platelet lysates, the natural healing system containing a mix of pleitropic NTF and having immunomodulatory function. This review highlights that this latter treatment may be crucial to power the neuroprotection and/or neurorestoration therapy requested in this devastating disease.
first_indexed 2024-12-23T20:16:15Z
format Article
id doaj.art-315ab431f7f8454d821621d82fbcc187
institution Directory Open Access Journal
issn 1664-2295
language English
last_indexed 2024-12-23T20:16:15Z
publishDate 2019-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Neurology
spelling doaj.art-315ab431f7f8454d821621d82fbcc1872022-12-21T17:32:40ZengFrontiers Media S.A.Frontiers in Neurology1664-22952019-08-011010.3389/fneur.2019.00835455919Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet LysatesFlore Gouel0Anne-Sophie Rolland1Jean-Christophe Devedjian2Thierry Burnouf3Thierry Burnouf4Thierry Burnouf5David Devos6David Devos7Department of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center, LICEND COEN Center, Lille, FranceDepartment of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center, LICEND COEN Center, Lille, FranceDepartment of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center, LICEND COEN Center, Lille, FranceGraduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, TaiwanInternational PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, TaiwanInternational PhD Program in Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, TaiwanDepartment of Medical Pharmacology, Lille University, INSERM UMRS_1171, University Hospital Center, LICEND COEN Center, Lille, FranceDepartment of Neurology, Lille University, INSERM UMRS_1171, University Hospital Center, LICEND COEN Center, Lille, FranceAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3–5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capacities in the central nervous system—e.g., development, plasticity, maintenance, neurogenesis—neurotrophic growth factors (NTF) have been exploited for therapeutic strategies in ALS for decades. In this review we present the initial strategy of using single NTF by different routes of administration to the use of stem cells transplantation to express a multiple NTFs-rich secretome to finally focus on a new biotherapy based on the human platelet lysates, the natural healing system containing a mix of pleitropic NTF and having immunomodulatory function. This review highlights that this latter treatment may be crucial to power the neuroprotection and/or neurorestoration therapy requested in this devastating disease.https://www.frontiersin.org/article/10.3389/fneur.2019.00835/fullAmyotrophic lateral sclerosisgrowth factorstherapeuticstem cellhuman platelet lysate
spellingShingle Flore Gouel
Anne-Sophie Rolland
Jean-Christophe Devedjian
Thierry Burnouf
Thierry Burnouf
Thierry Burnouf
David Devos
David Devos
Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates
Frontiers in Neurology
Amyotrophic lateral sclerosis
growth factors
therapeutic
stem cell
human platelet lysate
title Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates
title_full Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates
title_fullStr Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates
title_full_unstemmed Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates
title_short Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates
title_sort past and future of neurotrophic growth factors therapies in als from single neurotrophic growth factor to stem cells and human platelet lysates
topic Amyotrophic lateral sclerosis
growth factors
therapeutic
stem cell
human platelet lysate
url https://www.frontiersin.org/article/10.3389/fneur.2019.00835/full
work_keys_str_mv AT floregouel pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates
AT annesophierolland pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates
AT jeanchristophedevedjian pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates
AT thierryburnouf pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates
AT thierryburnouf pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates
AT thierryburnouf pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates
AT daviddevos pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates
AT daviddevos pastandfutureofneurotrophicgrowthfactorstherapiesinalsfromsingleneurotrophicgrowthfactortostemcellsandhumanplateletlysates